Brands of Teicoplanin in Kenya
Targocid®, Sanofi-aventis Kenya
Ticplat® ,Gufic Stridden Biopharma Private Ltd.
Mode of Action of Teicoplanin
Teicoplanin inhibits the growth of susceptible organisms by interfering with cell-wall biosynthesis at a site different from that affected by beta-lactams. Peptidoglycan synthesis is blocked by specific binding to D-alanyl-D-alanine residues.
Targocid is indicated in adults and in children from birth for the parenteral treatment of the following infections
- complicated skin and soft tissue infections,
- bone and joint infections,
- hospital acquired pneumonia,
- community acquired pneumonia,
- complicated urinary tract infections,
- infective endocarditis,
- peritonitis associated with continuous ambulatory peritoneal dialysis (CAPD),
- bacteraemia that occurs in association with any of the indications listed above.
Teicoplanin is also indicated as an alternative oral treatment for Clostridium difficile infection-associated diarrhoea and colitis.
Where appropriate, teicoplanin should be administered in combination with other antibacterial agents.
Hypersensitivity to teicoplanin or to any of the excipients
No specific interaction studies have been performed.
Teicoplanin and aminoglycoside solutions are incompatible and must not be mixed for injection; however, they are compatible in dialysis fluid and may be freely used in the treatment of CAPD-related peritonitis. Teicoplanin should be used with care in conjunction with or sequentially with other medicinal products with known nephrotoxic or ototoxic potential. These include aminoglycosides, colistin, amphotericin B, ciclosporin, cisplatin, furosemide, and ethacrynic acid . However, there is no evidence of synergistic toxicity in combinations with teicoplanin.
In clinical studies, teicoplanin has been administered to many patients already receiving various medications including other antibiotics, antihypertensives, anaesthetic agents, cardiac medicinal products and antidiabetic agents without evidence of adverse interaction.
ADVERSE DRUG INTERACTIONS:
Infections and infestations
Superinfection (overgrowth of non-susceptible organisms)
Blood and the lymphatic system disorders
Leucopenia, thrombocytopenia, eosinophilia
Immune system disorders
Anaphylactic reaction (anaphylaxis)
Drug reaction with eosinophilia and systemic symptoms (DRESS), anaphylactic shock
Nervous system disorders
Ear and Labyrinth disordersDeafness, hearing loss , tinnitus, vestibular disorder
Respiratory, thoracic and mediastinal disorders
Diarrhoea, vomiting, nausea
Skin and subcutaneous tissue disorders
Rash, erythema, pruritus
Red man syndrome (e.g. Flushing of the upper part of the body)
Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, angioedema, dermatitis exfoliative, urticaria
Renal and Urinary disorders
Blood creatinine increased
Reporting of suspected adverse reactions:
The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, firstname.lastname@example.org or clicking below button:
Teicoplanin in Kenya
Teicoplanin in Kenya
Teicoplanin in Kenya
Teicoplanin prices in Kenya
Clinical | Pharmacokinetic data
Routes of Administration: Intravenous, intramuscular
Bioavailability: 90% (given IM)
Protein Binding: 90% to 95%
Onset of Action:
Elimination Half life: 70 to 100 hours
Excretion: Renal (97% unchanged)
Legal Status | Dosage forms & Strengths
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This Drug is not Subject to DDA drugs Act
Dosage Forms | Strengths:
|CompTox Dashboard (EPA)|
- Reynolds, P. E. (Nov 1989). “Structure, biochemistry and mechanism of action of glycopeptide antibiotics”. European Journal of Clinical Microbiology and Infectious Diseases. 8: 943–950.